Amino acid mutations in Ebola virus glycoprotein of the 2014 epidemic

2015 ◽  
Vol 87 (6) ◽  
pp. 893-898 ◽  
Author(s):  
Marta Giovanetti ◽  
Alba Grifoni ◽  
Alessandra Lo Presti ◽  
Eleonora Cella ◽  
Carla Montesano ◽  
...  
2020 ◽  
Vol 15 (9) ◽  
pp. 2000069 ◽  
Author(s):  
Jasmin Heidepriem ◽  
Verena Krähling ◽  
Christine Dahlke ◽  
Timo Wolf ◽  
Florian Klein ◽  
...  

2006 ◽  
Vol 121 (2) ◽  
pp. 205-214 ◽  
Author(s):  
Onesmo M. Mpanju ◽  
Jonathan S. Towner ◽  
Jason E. Dover ◽  
Stuart T. Nichol ◽  
Carolyn A. Wilson

2003 ◽  
Vol 77 (2) ◽  
pp. 1069-1074 ◽  
Author(s):  
Ayato Takada ◽  
Heinz Feldmann ◽  
Ute Stroeher ◽  
Mike Bray ◽  
Shinji Watanabe ◽  
...  

ABSTRACT Ebola virus causes lethal hemorrhagic fever in humans, but currently there are no effective vaccines or antiviral compounds for this infectious disease. Passive transfer of monoclonal antibodies (MAbs) protects mice from lethal Ebola virus infection (J. A. Wilson, M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. Hart, Science 287:1664-1666, 2000). However, the epitopes responsible for neutralization have been only partially characterized because some of the MAbs do not recognize the short synthetic peptides used for epitope mapping. To identify the amino acids recognized by neutralizing and protective antibodies, we generated a recombinant vesicular stomatitis virus (VSV) containing the Ebola virus glycoprotein-encoding gene instead of the VSV G protein-encoding gene and used it to select escape variants by growing it in the presence of a MAb (133/3.16 or 226/8.1) that neutralizes the infectivity of the virus. All three variants selected by MAb 133/3.16 contained a single amino acid substitution at amino acid position 549 in the GP2 subunit. By contrast, MAb 226/8.1 selected three different variants containing substitutions at positions 134, 194, and 199 in the GP1 subunit, suggesting that this antibody recognized a conformational epitope. Passive transfer of each of these MAbs completely protected mice from a lethal Ebola virus infection. These data indicate that neutralizing antibody cocktails for passive prophylaxis and therapy of Ebola hemorrhagic fever can reduce the possibility of the emergence of antigenic variants in infected individuals.


2016 ◽  
Vol 467 (1) ◽  
pp. 117-120 ◽  
Author(s):  
A. A. Panina ◽  
T. K. Aliev ◽  
O. B. Shemchukova ◽  
I. G. Dement’yeva ◽  
N. E. Varlamov ◽  
...  

2018 ◽  
Vol 54 (12) ◽  
pp. 1417-1420 ◽  
Author(s):  
Joshua A. Rabinowitz ◽  
John C. Lainson ◽  
Stephen Albert Johnston ◽  
Chris W. Diehnelt

We demonstrate a platform to screen a virus pseudotyped with Ebola virus glycoprotein (GP) against a library of peptides that contain non-natural amino acids to develop GP affinity ligands.


2021 ◽  
pp. 1-13
Author(s):  
Salvatore Dimonte ◽  
Muhammed Babakir-Mina ◽  
Taib Hama-Soor ◽  
Salar Ali

<b><i>Introduction:</i></b> SARS-CoV-2 is a new type of coronavirus causing a pandemic severe acute respiratory syndrome (SARS-2). Coronaviruses are very diverting genetically and mutate so often periodically. The natural selection of viral mutations may cause host infection selectivity and infectivity. <b><i>Methods:</i></b> This study was aimed to indicate the diversity between human and animal coronaviruses through finding the rate of mutation in each of the spike, nucleocapsid, envelope, and membrane proteins. <b><i>Results:</i></b> The mutation rate is abundant in all 4 structural proteins. The most number of statistically significant amino acid mutations were found in spike receptor-binding domain (RBD) which may be because it is responsible for a corresponding receptor binding in a broad range of hosts and host selectivity to infect. Among 17 previously known amino acids which are important for binding of spike to angiotensin-converting enzyme 2 (ACE2) receptor, all of them are conservative among human coronaviruses, but only 3 of them significantly are mutated in animal coronaviruses. A single amino acid aspartate-454, that causes dissociation of the RBD of the spike and ACE2, and F486 which gives the strength of binding with ACE2 remain intact in all coronaviruses. <b><i>Discussion/Conclusion:</i></b> Observations of this study provided evidence of the genetic diversity and rapid evolution of SARS-CoV-2 as well as other human and animal coronaviruses.


PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0152527 ◽  
Author(s):  
Jinwoo Lee ◽  
Sonia M. Gregory ◽  
Elizabeth A. Nelson ◽  
Judith M. White ◽  
Lukas K. Tamm

1986 ◽  
Vol 7 (5) ◽  
pp. 213-216 ◽  
Author(s):  
Gianfranco Cossu ◽  
Mario Manca ◽  
Pier Giorgio Righetti ◽  
Elisabetta Gianazza ◽  
VÉRonique Baudin ◽  
...  

2006 ◽  
Vol 27 (9) ◽  
pp. 926-937 ◽  
Author(s):  
Yum L. Yip ◽  
Vincent Zoete ◽  
Holger Scheib ◽  
Olivier Michielin

Sign in / Sign up

Export Citation Format

Share Document